In reply: It is interesting that in the debate on prostate cancer screening, positions are not as far apart as a “debate” implies. I agree with Del Mar and colleagues that all the existing trials have “serious potential methodological flaws” and therefore cannot be taken as evidence that prostate-specific antigen (PSA) screening is effective — nor that it is ineffective. Both sides of the “debate” are consistent with the recent National Health and Medical Research Council conclusion that PSA testing may help some men and may not help others.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Loeb S, Roehl KA, Antenor JA, et al. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 2006; 67: 316-320.
- 2. Vickers AJ, Cronin AM, Björk T, et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 2010; 341: c4521.
- 3. Lilja H, Cronin AM, Dahlin A, et al. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 2011; 117: 1210-1219.
- 4. Bul M, van Leeuwen PJ, Zhu X, et al. Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam. Eur Urol 2011; 59: 498-505.
- 5. Vickers AJ, Ulmert D, Sjoberg DD, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ 2013; 346: f2023. doi: 10.1136/bmj.f2023.
No relevant disclosures.